Research programme: doublecortin-like kinase 1 inhibitors - COARE Biotechnology
Alternative Names: DCLK1 kinase inhibitors - COARE BiotechnologyLatest Information Update: 22 Feb 2022
Price :
$50 *
At a glance
- Originator COARE Biotechnology
- Class Antineoplastics
- Mechanism of Action DCLK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Colorectal cancer; Pancreatic cancer; Renal cancer
Highest Development Phases
- Research Colorectal cancer; Pancreatic cancer; Renal cancer
Most Recent Events
- 22 Feb 2022 Doublecortin-like kinase 1 inhibitors are still in research development for Colorectal cancer in USA (unspecified route) (COARE Biotechnology pipeline, February 2022)
- 22 Feb 2022 Doublecortin-like kinase 1 inhibitors are still in research development for Pancreatic cancer in USA (unspecified route) (COARE Biotechnology pipeline, February 2022)
- 22 Feb 2022 Doublecortin-like kinase 1 inhibitors are still in research development for Renal cancer in USA (unspecified route) (COARE Biotechnology pipeline, February 2022)